Bioventus(BVS)

Focus: Bioventus is a public orthobiologics company focused on musculoskeletal solutions including hyaluronic acid injectables, ultrasound-based bone healing devices, and neuromodulation systems. With ~$512M in annual revenue and 1,001-5,000 employees, it operates at the mid-cap biotech scale.

Profile data last refreshed 5h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

1001-5000

Open Jobs

About Bioventus

AI assessmentNot Hiring

No open roles listed right now. Follow Bioventus to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Early-stage

17 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$512M

Pipeline & Clinical Trials

Durolane

Osteoarthritis

N/A

Clinical Trials (1)

NCT02610504Prospective Single Center Open Label Study of Shoulder OA Pain

N/A

Help build intelligence for Bioventus

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Established public company with $512M stable revenue and recent Q1 2026 earnings beat, offering job security vs. pre-revenue startups
Focused orthobiologics niche with diverse product portfolio (injectables, devices, neuromodulation) spanning multiple musculoskeletal indications
Early-stage pipeline including Phase 2 (PTP-001) and Phase 1 programs with potential for clinical advancement in next 12-24 months

Watch Out For

Low R&D intensity (3%) and declining R&D spend ($24M in FY2024 to $13M in FY2025) signals limited research infrastructure investment and potential hiring constraints
Consistent net losses (~$156M in FY2025, ~$159M in FY2024) despite flat revenue and tight cash position ($42M) raise sustainability concerns
Minimal early-stage pipeline depth: only 1 Phase 2 and 1 Phase 1 program, zero Phase 3 programs, and no meaningful upcoming catalysts despite 17 total trials

Generated by Claude from Bioventus's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

ARTZ

Knee Osteoarthritis

N/A

Clinical Trials (1)

NCT01295580Comparative Study of Safety and Efficacy of Two Hyaluronic Acids for the Treatment of Knee Osteoarthritis Pain

N/A

Supartz

Osteoarthritis

N/A

low intensity, pulsed ultrasound

Knee Osteoarthritis

N/A

Clinical Trials (1)

NCT01623804Randomized Trial in knEe Osteoarthritis Using Low Intensity Ultrasound - Evaluating Feasibility (RELIEF)

N/A

Bioventus Exogen 4000: Low-intensity pulsed ultrasound

Nonunion of Fracture of Scaphoid Bone

N/A

Clinical Trials (1)

NCT02383160Scaphoid Non-union and Low-intensity Pulsed Ultrasound Trial

N/A

Exogen 4000+

Tibial Fractures

N/A

Clinical Trials (1)

NCT00667849Trial to Evaluate UltraSound in the Treatment of Tibial Fractures

N/A

Low intensity pulsed ultrasound

Mitigation of Fracture Non-union in Patients at Risk

N/A

Clinical Trials (1)

NCT03382483Observational, Non-interventional Use of LIPUS to Mitigate Fracture Non-union in Patients at Risk

N/A

OsteoAMP

Spondylolisthesis

N/A

Clinical Trials (1)

NCT02225444A Prospective Study of Instrumented, Posterolateral Lumbar Fusions (PLF) With OsteoAMP®

N/A

OSTEOAMP

Lumbar Spine Disease

N/A

Clinical Trials (1)

NCT05405374OSTEOAMP Lumbar Fusion Intra-Patient Controlled Study

N/A

Durolane SJ

Rhizarthrosis

N/A

Exospine sham

Lumbar Degenerative Disc Disease

N/A

Clinical Trials (1)

NCT00744861Ultrasound as Adjunct Therapy for Increasing Fusion Success After Lumbar Surgery

N/A

3ml hyaluronic acid

Knee Osteoarthritis

N/A

Clinical Trials (1)

NCT01543737Effectiveness of Two Hyaluronic Acids in Osteoarthritis of the Knee

N/A

StimRouter Neuromodulation System

Osteoarthritis, Knee

N/A

Clinical Trials (1)

NCT05644639Study of StimRouter for Chronic Knee OA Pain

N/A

SUPARTZ®

Osteoarthritis of the Shoulder

N/A

Clinical Trials (1)

NCT00479687SUPARTZ Versus Placebo in Osteoarthritis of the Shoulder

N/A

Biological: PTP-001

Knee Osteoarthritis

PHASE_1

Clinical Trials (1)

NCT04632966Safety Study of PTP-001 for Treating Knee Osteoarthritis

Phase 1

PTP-001

Osteoarthritis, Knee

PHASE_2

Clinical Trials (1)

NCT05100225Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis

Phase 2

Durolane SJ

Osteoarthritis

PHASE_4

Clinical Trials (1)

NCT0262785926 Week Open Label Study Evaluating Single IA Injection of DUROLANE SJ for Treatment of Osteoarthritis Pain of the Ankle

Phase 4

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 15 clinical trials

Publications: 25 in PubMed

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2025)

Revenue

$512M0%

R&D Spend

$13M(3%)44%

Net Income

-$156M

Cash

$42M

Source: SEC 10-K Filing

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Systematic evaluation of surgical insertion of flexible neural probe arrays into deeper brain targets using length modulation methods.

Journal of neural engineering

2026

PMID:41534114

Composition and Bioactivity of a Placental Tissue Particulate (PTP-001) Indicate Greater Potential than Platelet-Rich Plasma for the Treatment of Osteoarthritis.

Cartilage

2023

PMID:36912174

Showing 5 of 10 publications

Bioventus(BVS)

About Bioventus

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Bioventus(4)

Open Jobs (0)

Financials (FY2025)

Hiring Trend

Research Publications(10)